1. Home
  2. RPD vs NBTX Comparison

RPD vs NBTX Comparison

Compare RPD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

HOLD

Current Price

$12.65

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$21.37

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPD
NBTX
Founded
2000
2003
Country
United States
France
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
RPD
NBTX
Price
$12.65
$21.37
Analyst Decision
Hold
Strong Buy
Analyst Count
21
1
Target Price
$22.40
$8.00
AVG Volume (30 Days)
1.1M
36.0K
Earning Date
02-10-2026
09-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.35
N/A
Revenue
$858,667,000.00
$11,930,711.00
Revenue This Year
$2.62
N/A
Revenue Next Year
$1.58
$145.24
P/E Ratio
$36.31
N/A
Revenue Growth
3.08
N/A
52 Week Low
$12.61
$2.93
52 Week High
$40.25
$30.35

Technical Indicators

Market Signals
Indicator
RPD
NBTX
Relative Strength Index (RSI) 22.20 49.74
Support Level $13.22 $19.61
Resistance Level $13.97 $22.22
Average True Range (ATR) 0.53 1.05
MACD -0.18 -0.06
Stochastic Oscillator 0.32 46.32

Price Performance

Historical Comparison
RPD
NBTX

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: